Insulet Corporation (GOV.F)
- Previous Close
229.60 - Open
248.00 - Bid 273.10 x 12100
- Ask 274.40 x 11600
- Day's Range
248.00 - 274.70 - 52 Week Range
147.20 - 277.30 - Volume
30 - Avg. Volume
4 - Market Cap (intraday)
19.328B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
53.65 - EPS (TTM)
5.12 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
www.insulet.comRecent News: GOV.F
View MorePerformance Overview: GOV.F
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GOV.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GOV.F
View MoreValuation Measures
Market Cap
16.00B
Enterprise Value
16.38B
Trailing P/E
44.91
Forward P/E
62.11
PEG Ratio (5yr expected)
6.59
Price/Sales (ttm)
9.26
Price/Book (mrq)
15.07
Enterprise Value/Revenue
8.94
Enterprise Value/EBITDA
43.71
Financial Highlights
Profitability and Income Statement
Profit Margin
20.19%
Return on Assets (ttm)
6.80%
Return on Equity (ttm)
43.03%
Revenue (ttm)
2.07B
Net Income Avi to Common (ttm)
418.3M
Diluted EPS (ttm)
5.12
Balance Sheet and Cash Flow
Total Cash (mrq)
953.4M
Total Debt/Equity (mrq)
118.37%
Levered Free Cash Flow (ttm)
155.28M